The Diffusion of a Novel Therapy Into Clinical Practice

Authors:
  • JGJerry H. Gurwitz
    Jerry H. Gurwitz
  • TFTerry S. Field
    Terry S. Field
  • SASusan E. Andrade
    Susan E. Andrade
  • LFLeslie S. Fish
    Leslie S. Fish
  • PJP. David Jarry
    P. David Jarry
  • RYRobert A. Yood
    Robert A. Yood

Abstract
ERECTILE DYSFUNCTION is a common condition that is thought to affect between 20 and 30 million men in the United States,1 the majority of whom have never sought medical attention for the problem.2 With the availability of sildenafil (Viagra), there has been unprecedented public interest in the treatment of this condition.3 In the first 3 months that sildenafil was on the market, 3.9 million prescriptions were dispensed.4 The medication is even available for purchase over the Internet.5,6 The introduction of an effective oral medication has shifted the treatment of erectile dysfunction from specialists to primary care physicians.7 Most specialists in male impotence consider sildenafil the first-line therapy for erectile dysfunction.7